Michael DelahayeDirector of Cell Therapy BioProcessing: Cell Therapy, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals R&D at AstraZenecaSpeaker
Profile
Michael represents the BioPharmaceuticals R&D Cell Therapy Department at AstraZeneca, and brings with him over 15 years of industrial experience within the cell and gene therapy sector. His key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of cell therapies.
Previously, Michael held the position of Head of the Viral Vector Industrialisation team at the Cell and Gene Therapy Catapult. He’s led teams of experienced scientists within the Viral Gene Delivery program, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&D operations. Prior to that, he held roles at TAP Biosystems (now part of Sartorius Stedim) and completed his EngD in 2011 at UCL, which included multiple industrial collaborations.
Agenda Sessions
Developing ATMPs for commercialization: A large Pharma process approach from idea to a manufactured Cell Therapy product
, 09:00View Session